<DOC>
	<DOCNO>NCT00958568</DOCNO>
	<brief_summary>The purpose study determine whether olanzapine fluoxetine combination ( OFC ) use long time ( 47 week ) make patient suffer Treatment Resistant Depression stable , determine OFC safe use treat patient Treatment Resistant Depression long time ( 47 week ) , determine whether olanzapine fluoxetine combination fluoxetine alone well treat Treatment Resistant Depression treat long time ( 47 week ) assess quality life treatment .</brief_summary>
	<brief_title>A Study Relapse Prevention Treatment-Resistant Depression</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , active comparator-controlled , parallel study participant Treatment Resistant Depression ( TRD ) , compare efficacy safety olanzapine fluoxetine Combination ( OFC ) versus fluoxetine relapse prevention stabilize participant TRD . The study consist 4 phase : screening phase ; 6- 8-week open-label acute treatment phase ; 10- 12-week open-label stabilization phase ; 27- 29-week double-blind relapse prevention treatment phase . Participants demonstrate response open-label OFC acute treatment phase continue stabilization phase . Participants remain stable receive open-label OFC phase randomize receive either OFC fluoxetine double-blind relapse prevention phase . Investigators participant blind precise duration stabilization period , definition remission , criterion entry relapse prevention phase ; information describe supplement give Ethical Review Boards ( ERBs ) regulatory authority .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Have single recurrent unipolar Major Depressive Disorder ( MDD ) , without psychotic feature Diagnostic Statistical Manual Mental Disorders , Fourth EditionText Revision ( DSMIVTR ) clinical assessment , confirm structured clinician Interview DSMIV Axis 1 disorder ( SCIDI ) . If female childbearing potential , test negative pregnancy agree abstain sexual activity use medically accept mean contraception study . Use oral injectable contraception must initiate prior receive treatment . Have 17item Hamilton Depression ( HAMD ) score great equal 18 screen day treatment due receive first time . Have treatmentresistant depression , define demonstrated failure achieve satisfactory antidepressant response adequate separate treatment course least 2 different antidepressant within current episode MDD . Have diagnosis Parkinson 's disease relate disorder . Have current lifetime diagnosis follow accord DSMIV criterion : Schizophrenia , Schizophreniform Disorder , Schizoaffective Disorder , Delusional Disorder , Psychotic Disorder Not Otherwise Specified , Bipolar Disorder I II , Delirium type , Dementia type , Amnestic Disorder , SubstanceInduced Disorder , Psychotic Disorder due General Medical Condition . Have current diagnosis postpartum depression , MDD atypical feature , MDD seasonal pattern define DSMIV . Have paranoid , schizoid , schizotypal , antisocial , borderline personality disorder ( Axis II ) comorbid primary diagnosis , base DSMIV criterion . Have psychotic symptom within 1 month prior Screening demonstrate psychotic feature screen day treatment due assign first time determine investigator . Have DSMIV substance dependence/abuse willing avoid use substance ( include dependence nicotine caffeine ) , define SCIDI , within past 30 day . Are actively suicidal judgment investigator . Have one seizure without clear resolve etiology . Have leukopenia history leukopenia without clear resolve etiology , know history agranulocytosis participant 's lifetime . Have alanine aminotransferase ( ALT ) /serum glutamic pyruvic transaminase ( SGPT ) value great equal 2 time upper limit normal ( ULN ) perform laboratory aspartate aminotransferase ( AST ) /serum glutamic oxaloacetic transaminase ( SGOT ) value great equal 2 time ULN total bilirubin value great equal 1.5 time ULN time screen . Have acute , serious , unstable medical condition . Have illness death anticipate within 1 year intensive care unit hospitalization illness anticipate within 6 month . Have elevate prolactin level screen . Have Bazett 's correct QT interval ( QTc ) great 450 millisecond ( male ) great 470 millisecond ( female ) screen treatment due receive first time . Have receive electroconvulsive therapy ( ECT ) vagus nerve stimulation ( VNS ) treatment within current episode ; history failure adequate treatment course ECT VNS ; require ECT VNS time study participation . If receive psychotherapy , light therapy , , anticipate require change frequency/intensity treatment regimen cease treatment regimen duration study . Participants receive therapy upon study entry may begin therapy screen , treatment phase study . Have receive previous treatment clozapine . Have use monoamine oxidase inhibitor ( MAOI ) within 14 day prior screen expect need MAOI treatment time study 5 week participant discontinues study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>